Lisata Therapeutics Inc
LSTA
NASDAQ
Biotechnology
$1.09
USD
-0.04 (-3.54%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $10.45M
Volume 23.9K
Revenue
$100,000
TTM
-90.7%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-14.62M
TTM
+22.7%
YoY
Operating Cash Flow
$-12.32M
TTM
+24.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 |
YoY Growth | — | — | -90.0% | — | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 |
Selling, General & Administrative | 2.7 | 2.5 | 2.0 | 3.7 | 3.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.9 | 4.4 | 3.2 | 4.9 | 4.0 |
Operating Income | -4.9 | -4.4 | -3.1 | -4.9 | -4.0 |
EBITDA | -4.8 | -4.4 | -3.1 | -4.9 | -4.0 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | -0.1 | 1.0 |
Total Other Income / Expense | 0.2 | 0.2 | 0.1 | 0.1 | 1.1 |
Income Before Income Taxes | -4.7 | -4.2 | -3.0 | -4.9 | -2.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.4 | 0.0 |
Net Income | -4.7 | -4.2 | -3.0 | -4.5 | -2.9 |
Consolidated Net Income / Loss | -4.7 | -4.2 | -3.0 | -4.5 | -2.9 |
Net Income Attributable to Common Shareholders | -4.7 | -4.2 | -3.0 | -4.5 | -2.9 |
Basic EPS | -$0.54 | -$0.49 | -$0.34 | -$0.50 | -$0.32 |
Diluted EPS | -$0.54 | -$0.49 | -$0.34 | -$0.50 | -$0.32 |
Basic Shares Outstanding | 8.6M | 8.7M | 8.8M | 9.0M | 9.1M |
Diluted Shares Outstanding | 8.6M | 8.7M | 8.8M | 9.0M | 9.1M |